Intraaortic balloon pump fails to improve mortality rate in cardiogenic shock patients: The IABP-SHOCK II study

August 27, 2012, European Society of Cardiology

A balloon pump inserted in the aorta is currently the most widely used support device in the treatment of cardiogenic shock and, since its introduction in 1968, has been used in several million people. However, there is still only limited evidence that the intraaortic balloon pump (IABP), one of the oldest medical devices in cardiology, is actually beneficial for the patient. Only a few registry studies and clinical trials have shown that the IABP can improve blood pressure and the perfusion of the coronary arteries.

Based on these studies, international guidelines recommend the use of an IABP in patients with cardiogenic shock. However, because cardiologists are not entirely convinced of its efficacy, an IABP is currently used in only 25-40% of shock patients. It was for these reasons that the IABP-SHOCK II trial was designed, aiming to show that the IABP can improve mortality if used in conjunction with optimal and early reopening of the -related artery.

Approximately 5-10% of patients after a experience the complication of cardiogenic shock, a shock which results from an inability of the heart to meet the body's demand for oxygen. In Europe around 60-70,000 patients are diagnosed with cardiogenic shock each year. In the past decade mortality related to cardiogenic shock has been reduced, mainly by early reopening of the infarct-affected artery by early balloon inflation. Nevertheless, the mortality rate in these patients is still extremely high, with approximately 50% dying within the first 30 days.

The IABP-SHOCK II trial - the largest trial ever performed in cardiogenic shock - randomised 600 patients enrolled in 37 centres in Germany to either an IABP or conventional optimal medical treatment alone. The hypothesis tested was that the IABP could reduce the rate of mortality within 30 days.

However, the study found no reduction in 30-day mortality rate in the IABP group when compared to the having standard care alone. The primary results are shown in the Figure attached, with no effect over time between the two study groups. Several subgroups were also evaluated and here too there was no clear benefit found for the IABP.

Similarly, the IABP showed no improvement in blood pressure, no reduction in treatment time in the intensive care unit, no decrease in the duration or dose of drugs prescribed, and no improvement in organ . On the other hand, the trial results showed that the IABP did not induce complications, and was shown to be a safe device.

Presenting the results, Professor Holger Thiele from the University of Leipzig Heart Centre in Germany said: "This large multicentre trial was unable to show a benefit for the currently most widely used mechanical support device in cardiogenic shock."

Explore further: Intra-aortic balloon pumps do not reduce infarct size in patients with STEMI without cardiac shock

Related Stories

Intra-aortic balloon pumps do not reduce infarct size in patients with STEMI without cardiac shock

August 30, 2011
Intra-aortic balloon pump counterpulsation prior to PCI in patients with ST segment elevation MI does not reduce infarct size as measured by MRI, according to results from the Counterpulsation Reduces Infarct Size Acute Myocardial ...

Women with acute heart failure have similar in-hospital mortality to men but are less treated

August 27, 2012
Women with acute heart failure have similar in-hospital mortality to men but are less treated in the real world, according to results from the global ALARM-HF registry presented today at the ESC Congress 2012. The findings ...

Recommended for you

Studies reveal role of red meat in gut bacteria, heart disease development

December 10, 2018
In concurrent studies, Cleveland Clinic researchers have uncovered new mechanisms that demonstrate why and how regularly eating red meat can increase the risk of heart disease, and the role gut bacteria play in that process.

Predicting leaky heart valves with 3-D printing

December 10, 2018
More than one in eight people aged 75 and older in the United States develop moderate-to-severe blockage of the aortic valve in their hearts, usually caused by calcified deposits that build up on the valve's leaflets and ...

Study points to optimal blood pressure treatment for stroke patients

December 10, 2018
Aggressive treatment of hypertension in stroke patients could do more harm than good in the long term, according to a new study from researchers at the University of Georgia.

Team uses gene editing to personalize clinical care for family with cardiomyopathy

December 10, 2018
A little over a year ago, a 65-year-old woman with severe hypertrophic cardiomyopathy—a condition in which the heart's muscle becomes abnormally thick, potentially causing dangerous irregular heartbeats—had her genes ...

Increasing statins dose and patient adherence could save more lives

December 7, 2018
Thousands of heart attacks and deaths from cardiovascular disease could be prevented by patients taking higher doses of statins and taking the drugs as advised by doctors.

Progress made in transplanting pig hearts into baboons

December 6, 2018
A large team of researchers from several institutions in Germany, Sweden, Switzerland and the U.S. has transplanted pig hearts into baboons and kept them alive for an extended period of time. In their paper published in the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.